PURPOSE: 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560) is a structural analog of celecoxib. Recent studies suggested that SC-560 inhibits the in vivo proliferation of colon and breast cancer cells to an extent similar to that observed in celecoxib, and that SC-560 exerts their growth inhibitory effects in a cyclooxygenase-independent manner. METHODS: In the current study, we sought to investigate the mechanism by which SC-560 inhibits the growth of human lung cancer cells. RESULTS: SC-560 more potently inhibited the growth of human A549, H460, and H358 lung cancer cell lines compared with that of human BEAS-2B normal bronchial epithelial cells. SC-560-induced growth inhibition was mainly due to the induction of cell-cycle arrest at the G1 phase without apoptosis induction. SC-560 rapidly and dose-dependently induced the generation of reactive oxygen species (ROS), followed by accumulation of cells at the G1 phase. Antioxidant pretreatment blocked the cell-cycle arrest and growth inhibition induced by SC-560. Combination treatment with other ROS-inducing agents such as alpha-tocopheryl succinate (TOS) augmented cellular response against SC-560, leading to synergistic apoptosis induction and growth suppression. Our data also showed that the apoptosis induced by combination treatment with SC-560 and TOS was mediated through ROS-dependent caspase activation. CONCLUSION: Collectively, our results demonstrate that SC-560 acts in a ROS-dependent manner to induce growth suppression in human lung cancer cells.
PURPOSE:5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560) is a structural analog of celecoxib. Recent studies suggested that SC-560 inhibits the in vivo proliferation of colon and breast cancer cells to an extent similar to that observed in celecoxib, and that SC-560 exerts their growth inhibitory effects in a cyclooxygenase-independent manner. METHODS: In the current study, we sought to investigate the mechanism by which SC-560 inhibits the growth of humanlung cancer cells. RESULTS:SC-560 more potently inhibited the growth of human A549, H460, and H358 lung cancer cell lines compared with that of human BEAS-2B normal bronchial epithelial cells. SC-560-induced growth inhibition was mainly due to the induction of cell-cycle arrest at the G1 phase without apoptosis induction. SC-560 rapidly and dose-dependently induced the generation of reactive oxygen species (ROS), followed by accumulation of cells at the G1 phase. Antioxidant pretreatment blocked the cell-cycle arrest and growth inhibition induced by SC-560. Combination treatment with other ROS-inducing agents such as alpha-tocopheryl succinate (TOS) augmented cellular response against SC-560, leading to synergistic apoptosis induction and growth suppression. Our data also showed that the apoptosis induced by combination treatment with SC-560 and TOS was mediated through ROS-dependent caspase activation. CONCLUSION: Collectively, our results demonstrate that SC-560 acts in a ROS-dependent manner to induce growth suppression in humanlung cancer cells.
Authors: C Bezombes; I Plo; V Mansat-De Mas; A Quillet-Mary; A Nègre-Salvayre; G Laurent; J P Jaffrézou Journal: FASEB J Date: 2001-07 Impact factor: 5.191
Authors: J Neuzil; T Weber; A Schröder; M Lu; G Ostermann; N Gellert; G C Mayne; B Olejnicka; A Nègre-Salvayre; M Stícha; R J Coffey; C Weber Journal: FASEB J Date: 2001-02 Impact factor: 5.191
Authors: A Roller; O R Bähr; J Streffer; S Winter; M Heneka; M Deininger; R Meyermann; U Naumann; E Gulbins; M Weller Journal: Biochem Biophys Res Commun Date: 1999-06-16 Impact factor: 3.575
Authors: G A Piazza; A L Rahm; M Krutzsch; G Sperl; N S Paranka; P H Gross; K Brendel; R W Burt; D S Alberts; R Pamukcu Journal: Cancer Res Date: 1995-07-15 Impact factor: 12.701
Authors: J Esteban Castelao; Robert D Bart; Costanzo A DiPerna; Eric M Sievers; Ross M Bremner Journal: Ann Thorac Surg Date: 2003-10 Impact factor: 4.330